Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Victorian Clinical Genetics Services, |
RCV002470495 | SCV002768014 | uncertain significance | Multiple mitochondrial dysfunctions syndrome 6 | 2019-08-28 | criteria provided, single submitter | clinical testing | A heterozygous missense variant was identified, NM_004279.2(PMPCB):c.122G>A in exon 2 of 13 of the PMPCB gene. This substitution is predicted to create a minor amino acid change from arginine to lysine at position 41 of the protein, NP_004270.2(PMPCB):p.(Arg41Lys). The arginine at this position has low conservation (100 vertebrates, UCSC). It is located within the mitochondrial targeting sequence. In silico software predicts this variant to be benign (Polyphen, SIFT, CADD, Mutation Taster). The variant is present in the gnomAD population database at a frequency of 0.001% (4 heterozygotes, 0 homozygotes). The variant has not been previously reported in clinical cases. Based on information available at the time of curation, this variant has been classified as a VARIANT of UNCERTAIN SIGNIFICANCE (VUS). |
Ambry Genetics | RCV002571490 | SCV003705123 | uncertain significance | Inborn genetic diseases | 2021-07-09 | criteria provided, single submitter | clinical testing | The c.122G>A (p.R41K) alteration is located in exon 2 (coding exon 2) of the PMPCB gene. This alteration results from a G to A substitution at nucleotide position 122, causing the arginine (R) at amino acid position 41 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |